Digestive Health Clinical Research

Clinical Trials

Digestive Health

Benaroya Research Institute and Virginia Mason Medical Center conduct clinical trials to improve digestive health. The Center for Digestive Health at the Virginia Mason Medical Center is internationally known for bringing together experts to optimize care through innovations in research, education and a multidisciplinary approach to the treatment of digestive diseases.

Clinical Research Studies in Digestive Health

We have ongoing clinical research studies in several areas of digestive health. Studies labeled as “Enrolling” are actively recruiting new participants while studies labeled as “Closed to Enrollment” are still active but no longer seeking new participants. 

 

Please email Digestive Health Research or call (206) 341-1021 for more information.

 

 

Crohn's Disease

A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease
Principal Investigator: Tim Zisman, MD
Status: Enrolling

 


A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn's Disease Who Have participated in ADMIRE II Study
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
Status: Closed to Enrollment

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance Treatment for Patients with Moderately to severely active Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex perianal fistula(s) in patients with Crohn's disease over a period of 24 weeks and a follow up period up to 52 weeks. ADMIRE-CD II study
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

Crohn's Disease: Risankizumab versus Ustekinumab for Subjects with Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

GA29145-An Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severly Active Crohn's Disease Previously Enrolled in the Etrolizumab Phase II PRotocol GA29144
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

Ulcerative Colitis

A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: Enrolling

 


A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC)
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderate to Severe Ulcerative Colitis
Principal Investigator: James Lord, MD
Status: Closed to Enrollment

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment

Digestive Health Clinical Research Team Leadership

Laura Lockshon

Laura Lockshon

Clinical Research Manager, Center for Digestive Health; Clinical Research Program

Digestive Health Clinical Research Team Members

Emily Chesterfield

Emily Chesterfield

Clinical Research Coordinator, Center for Digestive Health; Clinical Research Program
Brooke Grubb

Brooke Grubb

Clinical Research Specialist, Center for Digestive Health; Clinical Research Program
Audrey Merz

Audrey Merz

Clinical Research Coordinator, Center for Digestive Health; Clinical Research Program
Micaela Rodriguez

Micaela Rodriguez Moncayo

Clinical Research Coordinator, Center for Digestive Health; Clinical Research Program
Cheryl Shaw

Cheryl Shaw

Clinical Research Lead, Center for Digestive Health; Clinical Research Program
Vy Trinh

Vy Trinh

Clinical Research Assistant, Center for Digestive Health; Clinical Research Program

Contact Us

Contact the Digestive Health Research team by clicking below or call us at (206) 341-1021.